A Powerful New Tool for Drug Discovery
AmberGen has demonstrated the power of Bead-AMS™ to perform label-free screening of drug-protein interactions. In one study reported in Nature’s Scientific Reports, two kinase-targeted drugs, Dasatinib and Brigatinib (AP26113), were simultaneously screened against a model 50-member kinase library formatted on a random bead-array. The array was scanned using MALDI Mass Spectrometry Imaging (MALDI-MSI) at the equivalent density of 495,000 beads in the footprint of a microscope slide, yielding 100% sensitivity for detecting known strong drug interactions with no false positives.
Safer and More Useful Drugs
A fundamental challenge in the drug discovery process is to develop compounds with high efficacy and minimal side-effects. AmberGen has pioneered and patented a new approach based on Bead-AMS™ for screening lead drugs for off-target interactions, against the entire human proteome, at an early stage in the drug discovery process. This will lower the cost of drug development and importantly lower risks of adverse drug side-effects. Furthermore, Bead-AMS™ will allow the discovery of new drug targets and the repurposing of existing drugs to new diseases.
Get in Touch
313 Pleasant St.
Watertown, MA 02472
- Dr. Gargey Yagnik joins AmberGen as Program Coordinator for Mass Spectrometry. In his previous position as a postdoctoral researcher at Sanofi Genzyme he developed new methods for MALDI-MSI tissue imaging. He received his Ph.D. from Iowa State University in analytical chemistry. January 2017
- AmberGen awarded two US Patents (9,334,530 and 9,523,680) providing broad coverage for its Bead-AMS™ technology December 2016